Subject(s)
Dermatitis, Allergic Contact/diagnosis , Drug Eruptions/diagnosis , Patch Tests/statistics & numerical data , Abdominal Pain/drug therapy , Adrenal Cortex Hormones/therapeutic use , Aged , Ambroxol/administration & dosage , Ambroxol/adverse effects , Ambroxol/chemistry , Dermatitis, Allergic Contact/drug therapy , Dermatitis, Allergic Contact/etiology , Dermatitis, Allergic Contact/physiopathology , Drug Eruptions/drug therapy , Drug Eruptions/etiology , Drug Eruptions/physiopathology , Erythema , Exanthema , Female , Histamine Antagonists/therapeutic use , Humans , PruritusABSTRACT
No disponible
No disponible
Subject(s)
Humans , Female , Aged , Ambroxol/adverse effects , Dermatitis, Contact/etiology , Patch TestsABSTRACT
Chenopodiacea/Amaranthacea pollen is an important cause of respiratory allergy around the world. The problem could be aggravated because in desert or desert-like countries, these weeds are used in greening programmes or as ornamental plants. As climate tendencies should maintain in future decades, relevance of Chenopodiacea/Amaranthacea pollen allergy will go up. Relationship between airborne pollen grains and symptoms may not follow conventional patterns, and a wide lag between pollen counts and symptoms has been observed. Allergens from Chenopodium album y Salsola kali are probably the best known. A mayor band protein of 40-43 kDa has been associated with the main Salsola kali allergen, named sal k 1 and now recognised as pectin methyltranspherase or glucose 3 phosphate dehidrogenase. Systemic immunotherapy is effective and safe, improving symptoms, medication intake and Quality of Life and also reduces cutaneous allergen response.
Subject(s)
Allergens/immunology , Chenopodiaceae/immunology , Desensitization, Immunologic , Pollen/immunology , HumansABSTRACT
Exotic wood species are used in the manufacture of furniture, musical instruments, tool handles, and other wooden items. Exposure to sawdust of the wood can produce dermatitis on exposed areas in woodworkers. We studied 7 patients, gaitas constructors who used caviuna wood to make their instruments. They developed dermatitis on exposed areas hours after they had begun to work with caviuna. We performed patch tests using the European standard series, caviuna sawdust sample, and a series of dalbergiones. 15 controls were performed. Two caviuna samples provided by a patient were analysed by thin-layer chromatography (TLC). Patch test with caviuna sawdust yielded positive reactions in all patients. 5 of the 7 sufferers reacted strongly to obtusaquinine and (R)-4-methoxydalbergione deriving from Dalbergia retusa, but also to sensitizers present in other rosewoods. Patch tests with R-3,4-dimethoxydalbergione deriving from Machaerium scleroxylum remained negative in the patients, as well as in control subjects. The TLC analysis of the samples showed that the woods could have been M. scleroxylum, D. cearensis or D. frustescens, but not D. retusa. In our patients, airborne contact dermatitis was caused by exposure to caviuna sawdust. The patients must have been in contact with different Dalbergia species and especially with D. retusa.
Subject(s)
Allergens/adverse effects , Dermatitis, Allergic Contact/diagnosis , Facial Dermatoses/diagnosis , Wood/adverse effects , Adult , Dermatitis, Allergic Contact/etiology , Dermatitis, Allergic Contact/pathology , Diagnosis, Differential , Facial Dermatoses/etiology , Facial Dermatoses/pathology , Female , Humans , Male , Middle Aged , Music , Patch TestsABSTRACT
BACKGROUND: The inhalation of Salsola kali pollen is a common cause of respiratory diseases in Europe and North America. OBJECTIVE: To evaluate the efficacy and safety of a depigmented and glutaraldehyde-polymerized therapeutic vaccine of S kali. METHODS: The trial was randomized, double-blind, and placebo-controlled using a rush protocol in the build-up phase. Sixty patients with rhinoconjunctivitis (19 also had mild asthma) were randomly allocated to receive either active treatment (polymerized extract) or placebo. The final distribution was 41 patients in the active and 19 in the placebo group. Side effects were registered. Symptom and medication scores and the number of days free of symptoms during the pollen season were assessed to evaluate the clinical efficacy. A Rhinoconjunctivitis Quality of Life Questionnaire was completed in the previous pollen season (before treatment) and during the pollen season 1 year later (in the trial). Dose-response skin tests were performed at baseline and at the end of the trial. RESULTS: There was a significant difference (P < .05) in symptom and medication scores between both groups during the pollen season, with the active group the one that had fewer symptoms and lower intake of medication. The number of days without symptoms was higher in the active group (P < .05). This group also had a significant improvement in the Rhinoconjunctivitis Quality of Life Questionnaire and a reduction in skin sensitivity. No moderate or severe systemic reactions were registered. CONCLUSION: Immunotherapy with this modified vaccine of S kali pollen is safe and efficacious to treat patients clinically sensitive to this pollen. CLINICAL IMPLICATIONS: Patients allergic to S kali (Russian thistle) can be successfully treated with immunotherapy to improve symptoms of allergic rhinitis and asthma, reduce medication use, and improve quality of life parameters.